Humanized IL-5 Antibody CDR Optimization for Eosinophil Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma, such as the use of steroidal medications, have significant side effects and there is a need for more effective and selective anti-IL-5 treatments to reduce eosinophil accumulation and improve lung function.
Innovation Solution
Development of monoclonal antibodies and antigen-binding fragments that specifically target IL-5 with high affinity and specificity, including humanized antibodies with optimized CDR regions, to inhibit IL-5 activity and reduce eosinophil-mediated inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal medications are used to treat asthma, then inflammation in lung is alleviated, but significant side effects occur
Solution Approach 1:
The patent extracts and targets a specific mediator (IL-5) involved in eosinophil accumulation and asthma pathogenesis, rather than using broad-spectrum steroidal medications. By developing monoclonal antibodies that specifically bind to IL-5, the treatment isolates and eliminates only the harmful factor (IL-5) responsible for eosinophil-mediated inflammation, thereby achieving therapeutic effect while minimizing side effects.
Solution Approach 2:
The patent changes the therapeutic approach from non-specific anti-inflammatory steroids to specific IL-5 blocking antibodies. This parameter change in treatment mechanism involves switching from suppressing all inflammation to selectively blocking IL-5 signaling, resulting in improved efficacy with reduced harmful effects.
2Reliability
If existing anti-IL-5 antibodies are used, then eosinophil accumulation is reduced, but there is room for improvement in efficacy and selectivity
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the antibody molecules, particularly the complementarity determining regions (CDRs). By carefully selecting and modifying CDR sequences to enhance binding affinity and specificity for IL-5, the treatment achieves improved selectivity and efficacy. The framework regions are designed to minimize immunogenicity while maintaining the localized high-affinity binding capability at the IL-5 interaction site.
Solution Approach 2:
The patent employs composite material principles by creating humanized antibodies that combine human framework regions with optimized CDR regions. This composite approach integrates the safety profile of human antibodies with the high-affinity binding characteristics of engineered CDRs, achieving both improved efficacy and reduced immunogenicity simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-5 antibodies demonstrate high specificity and affinity, reducing eosinophil levels, improving lung function, and providing effective treatment for asthma and other IL-5-related diseases with reduced immunogenicity and improved metabolic stability.
Implementation Method 1
The IL-5 antibodies demonstrate high specificity and affinity, reducing eosinophil levels
Implementation Method 2
inhibit IL-5 activity and reduce eosinophil-mediated inflammation
Data Source
AI summary
Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.